Alexion Uses Excess Cash To Buy Strikingly Similar Synageva

At a hefty $8.4 billion price tag for a clinical-stage company, Alexion is betting heavily that Synageva’s Kanuma, filed for approval at FDA and EMA, will become an ultra-orphan blockbuster like Soliris.